

5TH INTERNATIONAL

PIPAC

SYMPOSIUM

UNDERSTANDING
PERITONEAL METASTASIS



September 7th & 8th 2018

FONDATION DOSNE-THIERS, PARIS, FRANCE

CONGRESS PRESIDENTS: Olivier Glehen (Lyon, France),
Martin Hübner (Lausanne, Switzerland), Hyung-Ho Kim (Seoul, South Korea),
Michael Bau Mortensen (Odense, Denmark), Marc Pocard (Paris, France),
Marc Reymond (Tübingen, Germany), Jimmy So (Singapore)

www.pipac.fr

FINAL PROGRAM

FINAL PROGRAM

Friday, September 7th

5TH INTERNATIONAL

PIPAC

SYMPOSIUM

UNDERSTANDING PERITONEAL METASTASIS



07:15 Welcome desk opening

SESSION 1 – TECHNOLOGY SESSION

- 08:00 HINAT, *S. Reck (Stuttgart, Germany)*
- 08:15 PIPAC, *P. Horvath (Tübingen, Germany)*
- 08:30 ePIPAC, *I. Sautkin (Omsk, Russia)*
- 08:45 hPIPAC, *H. H. Kim (Seoul, South Korea)*

SESSION 2 – PHARMACOLOGY SESSION, PHASE-I STUDIES

- 09:00 Dose escalation study of PIPAC with oxaliplatin, *J. So (Singapore)*
- 09:15 PIPOX, *F. Dumont (Nantes, France)*
- 09:30 nab-Paclitaxel, *W. Willaert (Gent, Belgium)*
- 09:45 ePIPAC, *K. Rovers (Eindhoven, The Netherlands)*

10:00 Coffee break

SESSION 3 – STATE OF THE ART LECTURES

- 10:30 PIPAC in ovarian cancer: state of the art, *C. B. Tempfer (Herne, Germany)*
- 11:00 PIPAC in gastrointestinal cancer: state of the art, *M. Hübner (Lausanne, Switzerland)*
- 11:30 International Society for the study of Pleura and Peritoneum (ISSPP), *M. A. Raymond (Tübingen, Germany)*

12:00 Lunch

SESSION 4 – CLINICAL STUDIES: PHASE-2

- 13:00 PIPAC-GA1, *F. Struller (Tübingen, Germany)*
- 13:15 PIPAC-GA2, *V. Khomiakov (Moscow, Russia)*
- 13:30 PARROT, *G. Vizzielli (Rome, Italy)*
- 13:45 PI-CaP, *M. Robella (Turin, Italy)*
- 14:00 PIPAC-OPC2 & PIPAC-OPC3, *M. Graversen (Odense, Denmark)*

14:15 Pause

SESSION 5 – CLINICAL STUDIES: RANDOMIZED TRIALS

- 14:45 PMGA-PIPAC, *B. Rau (Berlin, Germany)*
- 15:00 uGI-PIPAC, *T. Goetze (Frankfurt, Germany)*
- 15:15 PIPAC in platin-resistant ovarian cancer: a randomized trial, *S. P. Somashekhar (Bangalore, India)*
- 15:30 Quality of life assessment under PIPAC therapy: a randomized trial, *S. P. Somashekhar (Bangalore, India)*
- 15:45 PIPAC-Estok, *C. Eveno (Paris, France)*
- 16:00 PIPAC-OV3, *N. Bakrin (Lyon, France)*
- 16:15 CRC-PIPAC 2, *K. Rovers (Eindhoven, The Netherlands)*
- 16:30 GC-PIPAC 2, *K. Rovers (Eindhoven, The Netherlands)*

16:45 Summary of the day

17:00 End of the day

19:30 Gala dinner

FINAL PROGRAM

Saturday, September 8th

5TH INTERNATIONAL

PIPAC

SYMPOSIUM

UNDERSTANDING PERITONEAL METASTASIS



WORKING GROUPS

ROOM A

08:00 PIPAC-OV3 trial study meeting*,
N. Bakrin (Lyon, France)

ROOM B

08:00 PRGS pathology meeting*,
W. Solass (Tübingen, Germany)

ROOM C

08:00 Workshop Scanning
Electron Microscope*,
C. Pape (Darmstadt, Germany)

ROOM E

08:00 PIPAC international registry*,
M. B. Mortensen (Odense, Denmark)

CONFERENCE ROOM

08:00 Free papers presentation,
W. Ceelen (Ghent, Belgium)
& *R. Wilson (Sidney, Australia)*

10:00 Coffee break

CHARLES SURH LECTURE

10:30 Laudatio, *M. A. Reymond*
(Tübingen, Germany)
From Huang Di to Henry Head -
2000 years of segmental
phenomena, *F. Beissner*
(Hanover, Germany)

INTERNATIONAL SOCIETY FOR THE STUDY OF PLEURA AND PERITONEUM

M. Pocard (Paris, France)
11:00 Creation of the society
Approval of statute
Election of the first president
Election of the executive committee
Press release
Official picture in the historical library
12:00 Award for the best communication,
W. Ceelen (Ghent, Belgium)
& *R. Wilson (Sidney, Australia)*
Invitation to the 6th PIPAC meeting,
Singapore 2019, *J. So (Singapore)*
12:15 Farewell, *M. Pocard (Paris, France)*

SCIENTIFIC COMMITTEE

GI TUMORS

Pr Clarisse Eveno
Dr Philipp Horvath
Pr Martin Hubner
Dr Florian Struller

GYNECOLOGY

Pr Clemens Tempfer

EXPERIMENTAL

Pr Wim Ceelen
Pr Marc Pocard
Pr Robert Wilson

PHARMACOLOGY

Dr Ranjita Sahoo

TECHNOLOGY

Pr Marc Reymond

CLINICAL, PATHOLOGY

Dr Wiebke Solass

STATISTICS

Dr Tarkan Jäger

ACKNOWLEDGMENTS

MAJOR SPONSOR

CAPNOMED

SPONSORS



*On invitation.

CAPNOMED

teufels.com

CAPNOPEN®

Proven to be safe in over
5000 clinical applications
worldwide



www.capnomed.de